Related articles

After vitamin C (ascorbic acid) is metabolised in the body, a proportion can be converted into oxalate. Because calcium oxalate is a major component of many common kidney stones, the relationship between vitamin C intake and kidney stone risk has long been debated.

This early review examined the available evidence from vitamin C absorption, renal handling, oxalate metabolism, urinary oxalate measurement, and population studies to assess whether higher vitamin C intake was associated with calcium oxalate kidney stones.

Vitamin C can be metabolised in the body to form oxalate, and urinary oxalate is an important contributor to the formation of calcium oxalate kidney stones.

This raises a practical clinical question: does higher vitamin C intake increase kidney stone risk? This large prospective study followed women over many years and provides population-level risk information that differs substantially from individual case reports.

After high-dose intravenous vitamin C is metabolised in the body, a proportion can be converted into oxalate. When oxalate production increases and the kidneys are unable to eliminate it effectively, calcium oxalate crystals may form and deposit within the renal tubules, contributing to kidney injury.

Cases such as this do not mean that high-dose intravenous vitamin C inevitably causes renal injury. However, they provide an important safety signal regarding the relationship between oxalate metabolism, renal excretory capacity, and individual risk factors.

After vitamin C (ascorbic acid) is metabolised in the body, a proportion can be converted into oxalate, which is then primarily eliminated through the kidneys.

When vitamin C exposure is extremely high and renal excretory capacity is simultaneously reduced, the balance between oxalate production and elimination may be disrupted, increasing the risk of calcium oxalate crystal deposition and acute kidney injury.

When patients or their families search for “high-dose vitamin C and cancer cells,” they are often looking for more than information about a nutrient. Behind this question lies a more pressing concern: Beyond standard cancer treatment, are there additional ways to support the body, maintain strength, and improve recovery?

Many people with cancer feel exhausted during chemotherapy, lose appetite, sleep poorly, or worry that repeated infections mean their body cannot keep going. That is often when they ask what high-dose vitamin C has to do with cancer. The answer is not to treat vitamin C as a “natural anticancer drug.” It is to ask whether, at the right time, dose, and under medical supervision, it can form part of integrative oncology care—helping patients maintain strength, quality of life, and the ability to complete planned treatment.

When cancer treatment, prolonged fatigue, or recurrent infections place the body under strain, many patients ask whether high-dose vitamin C can help restore energy, support immune function, or make it easier to complete planned therapy. This is not a question that can be answered with a simple “suitable” or “not suitable.” Intravenous vitamin C should only become a meaningful part of overall care after diagnosis, kidney function, medications, treatment timing, and personal goals have been taken into account.

After vitamin C (ascorbic acid) is metabolised in the body, a proportion can be converted into oxalate, which is then primarily eliminated through the kidneys.

In certain high-risk individuals, a substantial increase in oxalate burden may contribute to calcium oxalate crystal formation and deposition within the renal tubules. Renal function and previous kidney disease are therefore important safety considerations when high-dose intravenous vitamin C is being considered.

One important direction in research on high-dose intravenous vitamin C (intravenous ascorbate) is to examine whether it can be used alongside standard chemotherapy while maintaining an acceptable safety profile and potentially reducing some chemotherapy-related adverse effects.

In ovarian cancer research, investigators conducted laboratory, animal, and human clinical studies. For patients, one of the most relevant components was a small randomised clinical trial evaluating the safety and early clinical findings of adding intravenous vitamin C to carboplatin and paclitaxel.